MLN2480 is a potent and selective inhibitor of fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3), primarily utilized in the field of oncology for the research and development of cancer therapies. It targets specific signaling pathways involved in cancer cell proliferation and survival, particularly in tumors driven by FGFR alterations. This compound is often studied in preclinical and clinical settings to evaluate its efficacy in treating various types of cancers, such as melanoma and colorectal cancer, especially those resistant to conventional treatments. Researchers focus on its potential to enhance the effectiveness of existing therapies or to serve as a standalone treatment option. Its application extends to understanding molecular mechanisms in cancer biology, aiding in the development of personalized medicine approaches for patients with advanced or refractory malignancies.